Drug Formulary Review Archives – November 1, 2001
November 1, 2001
View Issues
-
Urgency for bioterrorism response plan increases during anthrax scare
-
Eptifibatide has long-term benefit, cost-efficiency
-
News Briefs: FDA charges drug makers with misleading marketing
-
News Briefs: Antidepressants may raise bleeding risk
-
News Briefs: Questions about drug cards
-
Drug Criteria & Outcomes: Pantoprazole intravenous
-
Drug Criteria & Outcomes: CroFab: A treatment for snakebites
-
Drug Criteria & Outcomes: EPS and sedation with phenothiazines reviewed
-
Voluntary Micronase recall
-
Topamax warnings stronger
-
Bioterrorism Watch: Clinicians must be voice of reason, reassurance now that bioterrorism battle has been joined
-
Bioterrorism Watch: Should clinicians get smallpox vaccinations?
-
APhA develops Pharmacist Response Center web site
-
In the Pipeline
-
New FDA Approvals